A phase II study of neoadjuvant and adjuvant chemotherapy with @entity10049 , @entity4181 , @entity901 and XXXX in the treatment of previously untreated advanced @entity420 .

@entity1 @entity901 @entity4181 @entity137 @entity66 @entity419 @entity1205 @entity10049 @entity420
OBJECTIVE: A complete pathologic response to neoadjuvant chemotherapy, without the use of radiation, has infrequently been reported in operable chemo-na  ve stage III @entity420 @entity1 . METHODS: Twenty-nine eligible @entity1 were enrolled in the study. Neoadjuvant therapy consisted of @entity10049 , @entity4181 , @entity901 and @entity1205 and was administered in two 4-week cycles. Following therapy, @entity1 underwent surgical resection. Those @entity1 having @entity66 were offered adjuvant chemotherapy. @entity1 having a complete pathologic response were not offered any further chemotherapy. RESULTS: Twenty-four out of 29 @entity1 finished neoadjuvant therapy and underwent curative esophagectomy. Two @entity1 were declared inoperable after treatment, and three @entity1 died prior to surgery. The median follow-up on all @entity1 was 20.2 months. Median progression-free survival and median overall survival were 13.6 and 21.4 months, respectively. Clinical response to neoadjuvant chemotherapy was seen in 21 out of 29 @entity1 (72.4%). Complete pathologic response with neoadjuvant chemotherapy was seen in 4 out of 24 @entity1 (16.7%). Those four @entity1 have been alive and progression-free for 20-37 months. Grade 3-4 @entity137 occurred in 16 of the 29 @entity1 during neoadjuvant therapy. Grade 3-4 @entity137 were seen in 6 out of 14 @entity1 during adjuvant therapy. @entity419 -positron emission tomography standardized uptake values of >= 8 correlated with better progression-free survival. CONCLUSION: @entity10049 , @entity4181 , @entity901 and @entity1205 regimen is active in @entity1 with @entity420 . @entity137 profiles are manageable. Neoadjuvant chemotherapy allowed achievement of complete pathologic response without radiation. @entity419 -positron emission tomography standardized uptake values might be prognostic.
